@Insanely frustrating to watch the speed of this field, where it’s taken 4 years to arrive at “huh, maybe a 5-day course of Paxlovid isn’t enough…oops, maybe 25 days isn’t enough, either…huh, I’m stumped”
Something like a longer course of an antiviral, combined with an mAb, combined with vhe baseline by now. It should’ve been the baseline a year ago when PolyBio started recommending it⬇️. It should’ve been the baseline a year before that, when the community was talking about it.
It’s even more frustrating that all of the solutions already exist, and the only issue is that nobody will run the trials. I’d personally like to see something like Ensitrelvir + VYD2311 + Nuvaxovid.